FDA ap­proves first of two UCB myas­the­nia gravis drugs, fol­low­ing Alex­ion and ar­genx’s lead

The FDA ap­proved UCB’s gen­er­al­ized myas­the­nia gravis treat­ment Rystig­go, with the Bel­gian drug­mak­er say­ing it is the first drug to get OK’d for the two …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.